Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of nab-paclitaxel plus
cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma
(PDA).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gayle Jameson Pancreatic Cancer Research Team
Collaborators:
Cancer Research and Biostatistics Clinical Trials Consortium Honor Health - Clinical Trials Translational Drug Development Translational Genomics Research Institute Virgina G. Piper Cancer Center - Clinical Trials